Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I haven't followed Advanced Cell's journey in about 6 months but am happy to catch up on them today after so long. I always liked them but the well known issues forced me to pan them each time I looked at them.
After reading the last 80 or so posts, I would encourage patience. They have a very positive future IF they can execute a secondary without too much dilution and get started with the Ph 2. Dilution being a sore point to long time investors here, for sure. I'm not concerned with the uplist because those things take care of themselves when they are executing their plan and have catalysts to drive the price.
My feeling is that things are not as bad OR as good as some make have made them out to be, and that the encouraging science will prevail with institutional investors because it gives them valid reasons to be optimistic about success. That's the perspective of someone who knows their past, been away for a while, but has come back with fresh eyes and likes what he sees.
I decided to, soon after posting this. Thanks.
Yes I will, will, will.
Undecided on a price, so I may just look for a hammer candlestick to mark the bottom.
This is in a bearish flag formation. Its likely to continue lower.
This company trades in Germany, and the Berlin Exchange is NOTORIOUS for naked short selling. Does anyone at VERICEL pay attention to this stuff? Get it off that exchange, its killing the stock price. Talk to CEO Gerald Commissiong at Amarantus about their experience. They had to go thru the trouble of getting their company removed from the exchange last year due to naked short attacks.
http://www.gurufocus.com/stock/VCEL
Question on Hep C / IFN-a therapy: How would using INFRADURE biopump reduce or eliminate the severe side effects of this therapy? What are the reported side effects?
Whoa, glad I got out yesterday.
"..blinded evaluators were able to identify accurately the RXI-109 treated site at the 3-month follow-up more frequently (54%) than when treatment was initiated immediately post scar revision surgery (24%) (p< 0.0001 Fisher exact 2-tailed)."
54% doesn't sound like enough at this point. Barely half. That's close to the odds of a coin flip/guessing.
From the chart, the market doesn't seem impressed either. No reaction.
The later into development, the more favorable partnership deals become. They don't have too much to show a potential partner at this time, but deals start to become more attractive- especially after phase 2 is completed. I'm for holding off on any partnership offer until later, unless it reflects true optimism in the science.
For only being in preclinical stage, its about right IMO. They will need to raise funds in the not too distant future to fund Ph 1 and 2, so sizable dilution is coming.
Yup, looks like Jason's article last week got it moving today.
http://bionapcfa.blogspot.com/
Whats with the NDA filing? Has it been submitted yet?
Thank you golfstar. I'm glad someone gets it.
Just on the face of it, there were 4m shares offered and insiders bought 3m? That made no sense at all.
Sigh.
Where are you getting your insider holdings numbers from?
Care to provide some links to these before and after numbers?
I have a completely different take on this section. Read it again please. They owned options/warrants PRIOR to this offering and 58.7% reflects common shares AND their warrants/options (fully diluted shares). That's all its referring to. There is nothing in this quote stating how many shares they bought in this offering. For that you'd need to see a list of subscribers.
Link to insider buying?
This isn't a rare disease we're talking about, and we're talking about finding only 14 people. What are they going to do in a Ph 3 trial when they need to find hundreds of participants? I don't want to count on the standards being relaxed. I see a big problem with execution, and at this share price, so does the market.
I just don't get why its so hard to enroll 14 participants when there are 150m people with HCV. It should NOT be this hard.
They really have to make more of an effort to do private placements. They can't afford any more days like today.
Not to worry. Just carry a clip board.
With results of the previous cohort being made public before each new cohort begins, we should have a good idea how effective each dose will be. It seems we should have a good idea of its efficacy long before the trial is over.
Has a time frame been given on when top line results should be expected for TT-034?
You are correct. Always best to go to the primary source.
Great critique of recent SA article on Genervon's trial results for ALS, which applies to CUR and BCLI.
http://smithonstocks.com/weakness-in-neuralstem-caused-by-seeking-alpha-article-presents-a-buying-opportunity-cur-2-69-buy/
Remember Genervon's trial had a very small number of patients too, so their efficacy numbers could change with a larger group.
They will need to if they ever intend to uplist and attract institutional investors who can't buy shares under $5.
I'm not getting back into this until a RS. Surprised it hasn't happened yet, but its coming. I expect ~1:20.
I got out right before the RS, but am looking for a re-entry point now that its had time to marinate.
The price is acting like this Ph 2 is pivotal. Its not and they will have to do them again with a larger group.
"..Fiorino says the phase II study is not large enough to demonstrate a statistically significant efficacy benefit favoring NurOwn. Instead, he hopes the study will show NurOwn can be administered safety and that ALS and muscle function tests trend favorably in the therapy’s direction.
“This is not a pivotal study and will not support approval, but hopefully, the results will be compelling enough to allow us to move ahead into the next, larger study where we can treat ALS patients with multiple doses of NurOwn,” said Fiorino."
Looks like this is why it popped this morning, but this part is not clear:
"..The first patient was enrolled into the phase II study last June and Brainstorm expects results to be ready in the first half of 2016."
Is this referring to the ph 2b also? Ph 2a is due this quarter.
Another good SA article on TNXP by an author I respect. He's strong on the statistical meaning of the trial data:
http://seekingalpha.com/article/2530735-the-clouds-silver-lining-beyond-tonixs-missed-phase-2-primary-endpoint-for-fibromyalgia?v=1412177801
A good SA article has me reconsidering my previous opinion on Tonix.
http://seekingalpha.com/article/2528515-tonix-is-a-buy-on-endpoint-circumstances?v=1412105379
I'll put it this way. Unless they find data from this trial that allows them to modify the trial design, they are toast.
You could have upgraded to first class on the Titanic too after it hit the iceberg. Leave it alone.
Its in a bullish ascending triangle with 24 the breakout point. Watch the volume to confirm.
And a Fib retracement point is close at 38.2%. Close enough for me.
Faked me right out of my socks!
Roberto Duran "No Mas"
Pedro Martinez, "Who's Your Daddy...The Yankees"
Saborte, "You win shorts".
Short traders are like mountain climbers. They're not on the level.